| Scholar Rock Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal | 06/24 07:00 | businesswire.com |
| Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 06/18 16:15 | businesswire.com |
| Scholar Rock Presents New Data from SRK-181 Phase 1 DRAGON Trial at ASCO 2024 Annual Meeting | 06/03 16:00 | businesswire.com |
| Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting | 05/28 08:00 | businesswire.com |
| Scholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity | 05/22 07:00 | businesswire.com |
| Scholar Rock to Participate in Upcoming Investor Conferences | 05/20 08:00 | businesswire.com |
| Scholar Rock to Host Investor Day on May 22, 2024 | 05/14 08:00 | businesswire.com |
| Scholar Rock Reports First Quarter 2024 Financial Results and Highlights Business Progress | 05/07 07:00 | businesswire.com |
| 3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains | 04/24 06:33 | investorplace.com |